MedWatch

Lundbeck sells preclinical drugs to former research exec

The focus on four psychiatric disorders has made Lundbeck sell off two preclinical research projects to a US-based company founded by the former Vice President of the company's US research department. Lundbeck may still profit from the drugs, as there is an option for milestones and royalties.

Two drugs originally developed as possible treatments for psychiatric disorders no longer fit with Lundbeck's business plan, and have therefore been sold. | Foto: Lundbeck

Danish pharmaceutical company Lundbeck has sold off two preclinical drug candidates to US Mindimmune Therapeutics following an active sales process prompted by the Danish company.

The sale is a consequence of the Lundbeck Group's strategy to focus exclusively on the four disorders depression, schizophrenia, Alzheimer's disease and Parkinson's disease. Therefore, others will now get the opportunity to continue the development of the potential drugs against chronic neuropathic pain and Huntington's disease.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Forsøgsordning med risikodeling ender med vag konklusion

Lægemiddelstyrelsen har nu evalueret forsøgsordningen med risikodeling på lægemiddelområdet, men det sparsomme erfaringsgrundlag og påvirkningen fra covid-19 gør det svært at drage håndfaste konklusioner, lyder det fra Lægemiddelstyrelsen.

Europæisk laboratorienetværk skal sikre bedre data

Et nyt netværk af "referencelaboratorier" som led i EU's sygdomsforebyggelse skal bane vejen for bedre data. Der er stadig plads til forbedring, når der skal forberedes på fremtidige pandemier, siger Europa-Kommissionen til MedWatch.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier